Investigation of the Differences in Activity between Hydroxycycloalkyl N1 Substituted Pyrazole Derivatives As Inhibitors of B-Raf Kinase by Using Docking, Molecular Dynamics, QM/MM, and Fragment-Based De Novo Design: Study of Binding Mode of Diastereomer Compounds

N1 substituted pyrazole derivatives show diverse B-Raf kinase inhibitory activities when different hydroxy-substituted cycloalkyl groups are placed at this position. Docking, molecular dynamics (MD) simulations, and hybrid calculation methods (Quantum Mechanics/Molecular Mechanics (QM/MM)) were performed on the complexes, in order to explain these differences. Docking of the inhibitors showed the same orientation that X-ray crystal structure of the analogous (1E)-5-[1-(4-piperidinyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-2,3-dihydro-1H-inden-1-one oxime. MD simulations of the most active diastereomer compounds containing cis- and trans-3-hydroxycyclohexyl substituents showed stable interactions with residue Ile463 at the entrance of the B-Raf active site. On the other hand, the less active diastereomer compounds containing cis- and trans-2-hydroxycyclopentyl substituents showed interactions with inner residues Asn580 and Ser465. We found that the differences in activity can be explained by considering the dynamic interactions between the inhibitors and their surrounding residues within the B-Raf binding site. We also explained the activity trend by using a testing scoring function derived from more reliable QM/MM calculations. In addition, we search for new inhibitors from a virtual screening carried out by fragment-based de novo design. We generated a set of approximately 200 virtual compounds, which interact with Ile463 and fulfill druglikeness properties according to Lipinski, Veber, and Ghose rules.

[1]  Jae Yoon Chung,et al.  QM/MM based 3D QSAR models for potent B-Raf inhibitors , 2010, J. Comput. Aided Mol. Des..

[2]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[3]  Mirko Zimic,et al.  Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors , 2011, J. Comput. Aided Mol. Des..

[4]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[5]  Yu-Quan Wei,et al.  Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[6]  Julio Caballero,et al.  Docking and quantitative structure–activity relationship studies for sulfonyl hydrazides as inhibitors of cytosolic human branched-chain amino acid aminotransferase , 2009, Molecular Diversity.

[7]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[8]  D. Berger,et al.  Discovery of highly potent and selective type I B-Raf kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[9]  A. Adjei,et al.  Inhibitors of Raf kinase and MEK signaling , 2007 .

[10]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[11]  Stephen Hanessian,et al.  A comparative docking study and the design of potentially selective MMP inhibitors , 2001, J. Comput. Aided Mol. Des..

[12]  Julio Caballero,et al.  Modeling of Cyclin-Dependent Kinase Inhibition by 1H-Pyrazolo[3, 4-d]Pyrimidine Derivatives Using Artificial Neural Network Ensembles , 2005, J. Chem. Inf. Model..

[13]  R. Abagyan,et al.  Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes* , 2005, Molecular & Cellular Proteomics.

[14]  Ilza Pajeva,et al.  Molecular basis of inactive B-RAF(WT) and B-RAF(V600E) ligand inhibition, selectivity and conformational stability: an in silico study. , 2009, Molecular pharmaceutics.

[15]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[16]  K. Morokuma,et al.  ONIOM: A Multilayered Integrated MO + MM Method for Geometry Optimizations and Single Point Energy Predictions. A Test for Diels−Alder Reactions and Pt(P(t-Bu)3)2 + H2 Oxidative Addition , 1996 .

[17]  Fernando D. González Nilo,et al.  Insights into the Structural Basis of N2 and O6 Substituted Guanine Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors: Prediction of the Binding Modes and Potency of the inhibitors by Docking and ONIOM Calculations , 2009, J. Chem. Inf. Model..

[18]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.

[19]  Anders Karlén,et al.  Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. , 2008, Journal of molecular graphics & modelling.

[20]  Mike Welch,et al.  Potent and selective pyrazole-based inhibitors of B-Raf kinase. , 2008, Bioorganic & medicinal chemistry letters.

[21]  Julio Caballero,et al.  2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives. , 2008, Bioorganic & medicinal chemistry.

[22]  Garland R. Marshall,et al.  VALIDATE: A New Method for the Receptor-Based Prediction of Binding Affinities of Novel Ligands , 1996 .

[23]  A. Giuliani,et al.  An in silico study of the molecular basis of B-RAF activation and conformational stability , 2009, BMC Structural Biology.

[24]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[25]  Jans H Alzate-Morales,et al.  A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity. , 2007, Biophysical journal.

[26]  Matthew Paul Gleeson,et al.  QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors , 2009, J. Chem. Inf. Model..

[27]  Ian A. Watson,et al.  Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. , 2009, Journal of medicinal chemistry.

[28]  Hieu T. Do,et al.  Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. , 2006, Cancer research.

[29]  Jans H. Alzate-Morales,et al.  A computational ONIOM model for the description of the H-bond interactions between NU2058 analogues and CDK2 active site , 2009 .

[30]  K. Morokuma,et al.  A NEW ONIOM IMPLEMENTATION IN GAUSSIAN98. PART I. THE CALCULATION OF ENERGIES, GRADIENTS, VIBRATIONAL FREQUENCIES AND ELECTRIC FIELD DERIVATIVES , 1999 .

[31]  Óscar Villacañas,et al.  Structural Analysis of the Inhibition of Cdk4 and Cdk6 by p16INK4a through Molecular Dynamics Simulations , 2002, Journal of biomolecular structure & dynamics.

[32]  M. Santoro,et al.  Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. , 2009, Biochimica et biophysica acta.

[33]  Ricardo Vivas-Reyes,et al.  Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA. , 2008, Bioorganic & medicinal chemistry.

[34]  Julio Caballero,et al.  Docking and Quantitative Structure–Activity Relationship Studies for the Bisphenylbenzimidazole Family of Non‐Nucleoside Inhibitors of HIV‐1 Reverse Transcriptase , 2008, Chemical biology & drug design.

[35]  Peng Xie,et al.  Identification of BRAF inhibitors through in silico screening. , 2008, Journal of medicinal chemistry.

[36]  Julio Caballero,et al.  Computational Study of the Interactions between Guanine Derivatives and Cyclin-Dependent Kinase 2 (CDK2) by CoMFA and QM/MM , 2010, J. Chem. Inf. Model..

[37]  Klaus R Liedl,et al.  Molecular docking studies of natural cholinesterase-inhibiting steroidal alkaloids from Sarcococca saligna. , 2003, Journal of medicinal chemistry.

[38]  Julio Caballero,et al.  2D Autocorrelation Modelling of the Inhibitory Activity of Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors , 2006, Bulletin of mathematical biology.

[39]  Jans H. Alzate-Morales,et al.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[40]  de novo design and synthesis of N-benzylanilines as new candidates for VEGFR tyrosine kinase inhibitors. , 2008, Organic & biomolecular chemistry.

[41]  J. Sebolt-Leopold,et al.  Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway , 2008, Clinical Cancer Research.

[42]  Julio Caballero,et al.  Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses. , 2008, Bioorganic & medicinal chemistry.

[43]  Michal Otyepka,et al.  Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors , 2011, J. Comput. Aided Mol. Des..

[44]  W. Bisson,et al.  Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies. , 2009, Journal of medicinal chemistry.

[45]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[46]  Julio Caballero,et al.  Computational Study on the Interaction of N1 Substituted Pyrazole Derivatives with B-Raf Kinase: An Unusual Water Wire Hydrogen-Bond Network and Novel Interactions at the Entrance of the Active Site , 2010, J. Chem. Inf. Model..